| Generics | Generic pharmaceutical formulations globally especially in the US, Europe, and Rest of World markets. | Regulatory approvals, manufacturing capabilities and global supply chain. | B2B and B2C; global pharmaceutical distributors, hospitals, and healthcare providers. | Specialty generics and complex oral solid doses. | 2747 | 23 | Product sales of oral solid dosages, injectables, and specialty generics. | Direct sales with market-driven pricing in regulated markets. | Increasing approvals and launches in regulated markets; expanding distribution networks. | Basalog, Tacrolimus, Labetalol, Esomeprazole |
| Biosimilars | Development, manufacture and marketing of biosimilar monoclonal antibodies and insulins worldwide. | Robust R&D, global manufacturing scale, regulatory expertise, and commercial alliances. | Healthcare providers, hospitals, and patients in regulated and emerging markets. | Monoclonal antibodies and insulin analogues. | 8930 | 68 | Sales of biosimilar products via direct and partner-led commercialization. | Product sales and licensing revenues with global partnerships. | Launches in US and Europe, expanding geographic footprint, and portfolio diversification to next-generation biologics. | Semglee (Insulin Glargine), Ogivri (Trastuzumab), Fulphila (Pegfilgrastim), ALZUMAb (Itolizumab) |
| Research | Contract Research, Development, and Manufacturing Organization (CRDMO) services including discovery to commercial manufacturing. | Strong scientific expertise, global client base, regulatory compliance, and proprietary platforms. | Global pharmaceutical, biotechnology, agrochemical companies, academic and non-profit institutions. | Integrated discovery through manufacturing services and biologics development. | 3586 | 27 | Fee-for-service contracts, long-term research partnerships, and milestone payments. | Contractual service fees, milestone-based and recurrent engagements. | Pharma outsourcing trends, integrated service offerings, expanding client base. | Syngene International services |
